Therapeutic vaccine platform to boost immune responses in Tuberculosis

Award Notice Posted

Solicitation number
PHS2025-1
Agency
Awarded
to L2 Diagnostics LLC
Set-aside
Total Small Business

Opportunity facts

Contract number
75N93025C00024 Federal contract award
Place of performance
New Haven, Connecticut 06525, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, has awarded contract 75N93025C00024 to L2 DIAGNOSTICS LLC for the development of a therapeutic vaccine platform designed to boost immune responses in Tuberculosis. The contract was awarded on August 1, 2025, with a total value of $599,471.00. This award represents a Total Small Business set-aside opportunity, indicating the agency's commitment to supporting small business participation in this critical public health research initiative. The contract focuses on advancing therapeutic vaccine technology specifically targeting tuberculosis treatment through enhanced immune system responses.

Notice text

Awarded contract 75N93025C00024 to L2 DIAGNOSTICS LLC for 599471.00 on 2025-08-01.

Notice history

6 of 10 notices listed here. See the rest on GovTribe.

Similar open opportunities

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors